Biomedical subjects

S U Devaskar

Publications and source records attributed to S U Devaskar.

At least 37 records · Page 2Linked to original sources

PubMed1998

The effect of intrauterine growth restriction upon fetal and postnatal hepatic glucose transporter and glucokinase proteins.

Employing immunohistochemical and Western blot analyses, we investigated the cellular localization (22-d fetal and 14-d postnatal animals) and concentrations (22-d fetal to 21-d postnatal animals) of rat hepatic glucose transporters (Glut 1 and Glut 2) and glucokinase in response to development and uteroplacental insufficiency with IUGR. Glut 1, the predominant fetal hematopoietic cellular isoform, persisted in postnatal hematopoietic islands and was noted minimally in fetal hepatic cellular membranes. A approximately 40% extrauterine decline in Glut 1 levels paralleled the decline in hematopoietic cells. IUGR increased the fetal hepatic Glut 1 levels in parallel with an expanded hematopoietic cell mass (p < 0.05). In contrast, IUGR failed to alter the 2-fold increase in extrauterine Glut 2 concentrations (1-7-d postnatal animals), the isoform found in fetal and postnatal hepatocytic cell membranes. Glucokinase, the nuclear enzyme, increased 25% postnatally. IUGR caused a 16% increase in fetal glucokinase levels and a approximately 25% decline at postnatal d 1 (p < 0.05) without a comparable change in the hepatocytic cell number (92 +/- 6 versus 86 +/- 4). We conclude that hepatic Glut 1 concentrations reflect the extramedullary hematopoietic cellular mass, whereas extrauterine Glut 2 changes herald the need for enhanced flexibility in hepatocytic glucose transport with the initiation of food ingestion. The age-related alteration along with the IUGR-induced compensatory changes in the nuclear-mitochondrial glucokinase levels attributes a critical role for this enzyme in perinatal hepatocytic glucose homeostasis.

Animals↗

PubMed1998

Effect of uteroplacental insufficiency upon brain neuropeptide Y and corticotropin-releasing factor gene expression and concentrations.

Various hypothalamic functions such as feeding behavior, energy expenditure, body weight gain, level of anxiety, and sexual maturation are mediated by a balance between the concentrations of neuropeptide Y (NPY) and corticotropin-releasing factor (CRF). To test the hypothesis that maternal uteroplacental insufficiency alters the offspring's brain NPY and/or CRF levels, we examined the effect of maternal uterine artery ligation with intrauterine growth restriction (IUGR) (p < 0.05) upon fetal (20 d) and postnatal (4, 14, and 21 d) brain NPY and CRF synthesis, concentrations, and regional distribution. An age-related increase in NPY (0.8 kb) and CRF (1.4 kb) mRNA levels with peak amounts at the 14-d postnatal age (p < 0.05) was observed. IUGR was associated with a 75% increase in fetal brain NPY mRNA levels (p < 0.05) with no change in NPY peptide, CRF mRNA and peptide amounts. Although the increase in NPY mRNA levels persisted postnatally (p < 0.05) at d 4 and 21, CRF mRNA amounts were 2.5-fold higher only in the 4-d IUGR (p < 0.05). Paralleling the mRNA changes, an age-related increase in RIA of NPY and CRF peptide concentrations was noted (p < 0.05). IUGR caused postnatal brain NPY and CRF peptide changes similar to corresponding mRNA levels (p < 0.05), despite normal postnatal circulating glucose, insulin, corticosterone, and leptin concentrations. The age-specific intergroup differences in the NPY and CRF peptide immunoreactivity appeared predominantly in the hypothalamic region. We conclude that maternal uteroplacental insufficiency causing IUGR leads to a pretranslational imbalance in the immediate (4 d) postnatal brain NPY and CRF peptide concentrations, thereby altering the developmental pattern. This alteration in NPY and CRF peptide concentrations, despite normalization of the metabolic milieu was associated with a persistent diminution in body weight. The IUGR-associated pretranslational increase in NPY and not CRF peptide levels at d 21, may herald changes in feeding behavior during the postsuckling phase.

Animals↗

PubMed1997

Developmental changes in ob gene expression and circulating leptin peptide concentrations.

We examined the developmental changes in murine white and brown adipose tissue leptin and circulating immunoreactive total leptin concentrations. The approximately 4.4 kb leptin mRNA levels were higher at 2 and 7d postnatal ages, but declined to adult levels by the 14d stage and remained so until 160d. Paralleling the mRNA concentrations, leptin peptide levels also were higher at 2d, 7d, and 14d, declining to adult values by the 21d weaning stage. No difference in mRNA levels was observed between brown-enriched and white adipose tissue. No sexual dimorphism was observed in the leptin mRNA or peptide levels between 14 and 160d; however, at 2 and 7d, while no sex related differences were observed in the peptide levels, adipose mRNA concentrations were mildly higher in males than in the females. We conclude that leptin mRNA and peptide levels are higher during consumption of a high fat milk diet. High levels of leptin with increasing food intake and body weight gain signify hypothalamic leptin receptor resistance during the immediate postnatal period.

Adipose Tissue↗

PubMed1997

Insulin gene expression in immortalized rat hippocampal and pheochromocytoma-12 cell lines.

Employing reverse transcription-polymerase chain reaction and clonal cell lines derived by retroviral transduction of the temperature sensitive simian virus 40 large T-antigen into dispersed rat embryonic hippocampal cells, we detected the ancestral gene-insulin II mRNA in three progenitor subcloned cell lines. These cell lines upon differentiation are known to express markers indicative of commitment to either neuronal (H19-7; NF + , GFAP -), glial (H19-5; GFAP +, NF -), or bipotential (H583-5, NF +, GFAP + ) lineages. No duplicated, i.e., insulin I gene expression, was observed in any of the three cell lines. Induction of differentiation was associated with the persistence of insulin II mRNA and in the cells expressing a neuronal phenotype (H19-7; NF +, GFAP -) a relative doubling in insulin II mRNA level was present (P < 0.05). Minimal cellular insulin immunoreactivity was detected only in a subpopulation of cells with a differentiated neuronal phenotype. Radioimmunoassayable insulin peptide in the H19-7 cellular conditioned medium revealed a 5-fold increase in the differentiated state. In contrast, peripheral sympathetic PC-12 neuronal cells both in the undifferentiated and nerve growth factor-driven differentiated states, failed to express both insulin I and insulin II genes. We conclude that insulin II is expressed by cultured rat hippocampal clonal cell lines, and not by the peripheral sympathetic PC-12 neuronal cell line.

Animals↗

PubMed1997

Effect of maternal diabetes upon fetal rat myocardial and skeletal muscle glucose transporters.

We investigated the effect of streptozotocin-induced short-term maternal diabetes upon fetal rat myocardial and skeletal muscle glucose transporter Glut 1 (basal form) and Glut 4 (insulin-responsive form) protein concentrations by Western blot analysis. In the severely diabetic group (SEVERE-D, n = 17), a 3-fold increase in maternal and fetal glucose concentrations (p < 0.01) was associated with a 3-fold decline in maternal (p < 0.01) with no change in fetal insulin levels when compared with the streptozotocin-treated nondiabetic (n = 10) and vehicle-treated control (control, n = 14) groups. These changes in the SEVERE-D group when compared with controls were associated with a 30 and 65% decline, respectively, in fetal myocardial and skeletal muscle (forelimb and hind limb) Glut 1 protein concentrations. The fetal myocardium also demonstrated a 45% decline in Glut 4 protein levels. Fetal skeletal muscle Glut 4 protein, which was expressed only at very low levels in controls showed no change in SEVERE-D. Immunohistochemical analysis revealed a myocyte-plasma membrane association of Glut 1 and an intracellular Glut 4 distribution in the fetal myocardium and skeletal muscle. No Glut 1 immunoreactivity was noted in either the fetal myocardial or skeletal muscle perineural sheaths, blood vessels, or the entrapped fetal red blood cells. This subcellular localization pattern was unaltered in all three treatment groups. We conclude that maternal diabetes causing fetal hyperglycemia with normoinsulinemia suppresses fetal myocardial Glut 1 and Glut 4 and fetal skeletal muscle Glut 1. The decline in the plasma membrane associated Glut 1 concentrations may serve a protective function by reducing the glucose transport rate into fetal myocardial and skeletal muscle cells, which otherwise could be vulnerable to high circulating glucose. The in-utero maternal diabetes induced decrease in fetal myocardial intracellular-Glut 4 concentration could herald the emergence of insulin resistance.

Animals↗

PubMed1997

Effect of streptozotocin-induced maternal diabetes on fetal rat brain glucose transporters.

Glucose, an essential substrate for brain oxidative metabolism, is transported across the blood-brain barrier and into neuronal and glial cells via Glut 1 and Glut 3 facilitative glucose transporter isoforms. To examine the effect of excessive circulating glucose on fetal brain glucose transporter expression, we investigated the effect of streptozotocin-induced maternal diabetes (SEVERE-D; n = 29) on the 20-d gestation fetal rat brain Glut 1 and Glut 3. We studied the effect of streptozotocin alone (STZ-ND; n = 12) in a nondiabetic state as well, along with vehicle injected controls (C; n = 24). In the presence of fetal hyperglycemia (12.63 +/- 0.82 nM-SEVERE-D versus 2.35 +/- 0.28-STZ-ND and 2.42 +/- 0.16-C; p < 0.001) and hypoinsulinemia (0.38 +/- 0.03 nM-SEVERE-D versus 0.50 +/- 0.07-STZ-ND and 0.55 +/- 0.06-C; p < 0.02), no detectable change in fetal brain Glut 1 and Glut 3 pretranslational expression (transcription/elongation rates and corresponding steady state mRNA levels) was noted when simultaneously compared with the STZ-ND and C groups. In contrast, a trend toward a decline in Glut 1 (approximately 25 to 30%, p = 0.05) and a substantive decrease in Glut 3 (approximately 35 to 50%, p = 0.0006) protein concentrations was present in both the STZ-ND and SEVERE-D groups when compared with the C group. These observations support a chemical effect of streptozotocin independent of maternal diabetes upon the translation or posttranslational processing of fetal brain glucose transporters. Maternal diabetes with fetal hyperglycemia, however, failed to substantively alter fetal brain glucose transporters independent of the streptozotocin effects upon neuroectodermally derived tissues. We conclude that maternal diabetes with associated overt fetal hyperglycemia does not significantly change fetal brain glucose transporter levels.

Analysis of Variance↗

PubMed1997

Maternal diabetes-induced hyperglycemia and acute intracerebral hyperinsulinism suppress fetal brain neuropeptide Y concentrations.

We examined the effect of streptozotocin-induced maternal diabetes of 6-day duration and 4- to 24-h intracerebroventricular and systemic hyperinsulinism on fetal brain neuropeptide Y (NPY) synthesis and concentrations. Maternal diabetes (n = 6) leading to fetal hyperglycemia (5-fold increase; P < 0.05) and normoinsulinemia caused a 40% decline (P < 0.05) in fetal brain NPY messenger RNA (mRNA) and a 50% decline (P < 0.05) in NPY radioimmunoassayable levels compared to levels in streptozotocin-treated nondiabetic (n = 7) and vehicle-treated control (n = 8) animals. In contrast, systemic hyperinsulinemia (n = 7) of 5- to 100-fold increase (P < 0.05) over the respective control (n = 7) with normoglycemia caused an insignificant (20-30%) decrease in fetal brain NPY mRNA and protein concentrations. However, fetal intracerebroventricular hyperinsulinism (n = 7) with no change in fetal glucose concentrations caused a 50-60% decline (P < 0.05) in only the NPY peptide levels, with no change in the corresponding mRNA amounts. We conclude that fetal hyperglycemia of 6-day duration and intracerebroventricular hyperinsulinism of 4-24 h suppress fetal brain NPY concentrations, the former by a pretranslational and the latter by either a translational/posttranslational mechanism or depletion of intracellular secretory stores. We speculate that fetal hyperglycemia and intracerebroventricular hyperinsulinism additively can inhibit various intrauterine and immediate postnatal NPY-mediated biological functions.

Acute Disease↗

PubMed1996

Cell-specific localization of glucose transporter proteins in mammalian lung.

Mammalian lung uses glucose for cellular oxidative metabolism, growth, differentiation, surfactant synthesis, and host defense. Intracellular transport of glucose is accomplished by membrane-associated glycoproteins termed glucose transporters (Gluts). To determine the cell-specific localization patterns, human autopsy lung tissue from preterm (24-32 weeks; n = 4), term infants (38-40 weeks; n = 4), and adults (n = 4) was analyzed for facilitative Glut isoforms and the energy-dependent sodium-glucose cotransporters (SGLT) by Western blot analysis and immunohistochemistry. Antibodies specific for human Glut-1 (erythrocyt, blood-brain barrier type), Glut-3 (brain), Glut-4 (insulin-responsive skeletal muscle/adipocyte), and Glut-5 (kidney/jejunum) were employed. Analysis of Glut-2 (liver/pancreatic beta-cell/small intestine) was performed in newborn and adult rat lungs, and analysis of SGLT1 (kidney/small intestine) was conducted in newborn and adult rabbit lungs, because of the species specificity of the antirat Glut-2 and antirabbit SGLT1 antibodies employed. In human lung at all ages, our studies revealed an approximately 45- to 50-kDa Glut-1 protein band in entrapped erythrocytes and perineural sheaths, which serve as a blood-nerve barrier. In the rat lung, an approximately 45-kDa Glut-2 band was seen in the rat bronchial columnar epithelium. Glut-3 was observed in term infant and adult white blood cells and neuroendocrine cells, representing neuronal elements of the autonomic nervous system. Glut-4, Glut-5, and SGLT1 were not detected in lung. We conclude that Gluts are expressed in nonalveolar lung cell types arising from stem cells of the erythroid cell lineage and tissue barrier epithelia (Glut-1), foregut epithelium (Glut-2), myeloid cell lineage (Glut-3), and neuroectoderm (Glut-3). No detectable levels of Glut-4, Glut-5, or SGLT1 Gluts were noted in mammalian lung. The absence of a Glut isoform in the alveolar lining epithelial cells suggests minimal expression of the Glut isoform or the presence of some other transport system, reliance on adjacent cells for substrate supply, or uptake of nonglucose substrate to fuel a relatively low glucose-demanding cellular system.

Adult↗

PubMed1994

Insulin gene expression and insulin synthesis in mammalian neuronal cells.

To demonstrate the presence of de novo synthesis in central mammalian neurons, we cloned and sequenced a rabbit insulin cDNA from pancreas and used it to define sequences encoding insulin mRNA from postnatal rabbit brain. We observed transcription/elongation of nascent insulin transcripts, characterized the size of these transcripts, and localized them to specific neurons in certain catecholaminergic-rich areas of the central nervous system. RNase protection assays using a rabbit probe spanning a region from 14 bases 5' to the translation start site through all but 18 bases of the sequence encoding the A-chain of insulin showed two bands in rabbit brain RNA and only one band in pancreas. The larger band in brain was the same size as that in pancreatic RNA; the other was approximately 10 bases shorter. Because the sequence of a reverse transcription-polymerase chain reaction product from brain RNA was identical to pancreatic RNA sequence in the region corresponding to the 3' region of the probe, the smaller band in brain is most consistent with a sequence mismatch in some brain mRNA in the region corresponding to the 5'-end of the probe. In situ hybridization localized insulin mRNA to anatomical regions involved with olfaction and higher association of the limbic system. High performance liquid chromatography, radioimmunoassay, and [35S]cysteine metabolic labeling of cultured neuronal and glial cells indicated extracellular secretion of immunoprecipitable insulin by neurons only. Presence of insulin transcripts within specific neurons with extracellular secretion of the peptide suggests a specialized biological role.

Aging↗

PubMed1994

Expression of genes involved in placental glucose uptake and transport in the nonobese diabetic mouse pregnancy.

OBJECTIVE: Maternal diabetes alters placental glucose metabolism and maternofetal glucose transport. The purpose of this study was to determine whether genes involved in placental glucose uptake and transport were concomitantly altered, resulting in the observed changes in the state of maternal diabetes. STUDY DESIGN: By means of the nonobese diabetic pregnant mouse we examined the expression of placental glucose transporters, hexokinase I, glycogen content, glycogen-regulating enzyme activities in control animals (blood glucose 8.5 +/- 0.2 mmol/L, n = 25), moderate maternal diabetes (blood glucose 10 to 13.9 mmol/L, n = 16), and severe maternal diabetes (blood glucose > 16.7 mmol/L, n = 12). Comparisons by the analysis of variance and the Newman-Keuls test were performed. RESULTS: Although changes in placental glucose transporters and hexokinase I messenger ribonucleic acid levels occurred, neither state of diabetes altered the corresponding protein levels. Changes in placental deoxyribonucleic acid (p < 0.05) and glycogen content (p < 0.01), fetal insulin levels (p < 0.02), and fetal size (p < 0.05) occurred in the moderately diabetic group, and changes in placental weight (p < 0.05) and fetal glucose levels (p < 0.02) were observed in the severely diabetic group. CONCLUSIONS: Placental glucose transporting and phosphorylating protein levels by themselves do not regulate diabetes-induced fetoplacental alterations. The lack of a protective decline in these proteins may account for the observed fetoplacental adaptations to excess glucose.

Animals↗

PubMed1993

Insulin II gene expression in rat central nervous system.

Controversy persists concerning the origin of insulin in the central nervous system. While there has been convincing evidence in vitro to demonstrate the presence of neuronal insulin mRNA, conventional assays have failed to detect the same in whole brain preparations. Here we employed RNAse-protection and sensitive reverse transcription-polymerase chain reaction (RT-PCR) assays in attempts to detect insulin I and II mRNAs in rat brains obtained from different developmental stages. The RNAse-protection assay did not detect insulin I or insulin II transcripts in fetal (13 to 21 day gestation) or adult brains. RT-PCR, while detecting low amounts of insulin I transcripts in other extrapancreatic tissues such as the rat yolk sac and fetal liver previously shown to express insulin II, failed to detect insulin I in brain at any age examined. Insulin II mRNA was detected by RT-PCR in fetal, neonatal and adult rat brains, just as in yolk sac, fetal and adult livers. We conclude that while the duplicated insulin I gene is not expressed, the ancestral insulin II gene is expressed in fetal, neonatal and adult rat brains. Our observations support the concept of de novo brain insulin II synthesis beyond the pre-pancreatic stage of embryonic development.

Aging↗

PubMed1993

The developmental pattern of rabbit brain insulin and insulin-like growth factor receptor expression.

To examine the effect of development on rabbit brain insulin and insulin-like growth factor (IGF) receptor expression, we characterized and quantitated receptor mRNAs by Northern blot analysis and affinity-labeled ligand bound receptors by SDS-PAGE and autoradiography. At various stages of development ranging from 23 to 30 day gestational (term approximately 31 days), 1 to 10 day postnatal ages and the adult, no change in the whole brain insulin receptor mRNA (7.0, 6.0 and 5.5 kb) and affinity-labeled receptor protein (approximately 125 kDa) levels was observed. The IGF-I receptor mRNA (11.5, 6.5 and 4.5 kb) and affinity-labeled receptor (approximately 125 kDa) protein levels declined during the neonatal stages of development. In the case of the IGF-II receptor, while the mRNA levels (9.0 and 4.5 kb) remained constant, the corresponding affinity-labeled receptor protein (approximately 230 kDa) declined with maturation. We conclude that a differential regulation of brain insulin, IGF-I and IGF-II receptor expression occurs during development.

Animals↗

PubMed1993

Jejunal/kidney glucose transporter isoform (Glut-5) is expressed in the human blood-brain barrier.

The recently cloned Glut-5, glucose transporter isoform, is expressed in human jejunum and kidney. Employing previously characterized polyclonal antibodies directed towards the C-terminus region of the derived human Glut-5 peptide and Western blot analysis, a 50-55 kilodalton Glut-5 protein was detected in adult human brain homogenates. The amount of Glut-5 protein in brain was 4-fold lower when compared to the levels in adult kidney. Immunohistochemical analysis using cerebral and cerebellar sections demonstrated Glut-5 immunoreactivity in only some of the Glut-1 and factor VIII-positive brain microvascular endothelial cells, the intravascular red and white blood cells being negative. This selective localization pattern was confirmed by the 5-fold enrichment of Glut-5 vs. a 20-fold enrichment of Glut-1 in an isolated human cerebral cortical microvascular preparation, when compared to whole cerebral homogenates. We conclude that Glut-5 is localized in the endothelial cells of human brain microvasculature. Unlike other fructose using tissues, where Glut-5 may subserve the role of a fructose carrier, in brain where fructose is not used as a substrate, Glut-5 may transport glucose alone. This role of Glut-5 in conjunction with the previously characterized brain endothelial Glut-1 and Glut-3 needs further elucidation.

Blood-Brain Barrier↗

PubMed1993

Characterization of glucose transporter isoforms in the adult and developing human eye.

The expression of glucose transporter isoforms (Glut 1, Glut 3, Glut 4, and Glut 5) in the human eye was investigated at various ages ranging between 8 weeks gestation (first trimester) and adult using Western blot and immunohistochemical analyses. Glut 1 and Glut 3 expression and cellular localization patterns were similar to those of human brain. Glut 1 (50-kilodalton protein) was expressed by epithelial cells (retinal pigmented epithelium, choroidal, iridial, and pars planus), which form the blood-eye barrier, retinal Mueller cells, the lens fiber cells, iridial microvascular endothelial cells, and to a lesser extent by the outer segments of the photoreceptor cells in the adult eye. This pattern was conserved throughout development and was evident as early as 8 weeks gestation. In addition, the endothelial cells of vitreous hyaloid vessels expressed Glut 1 at 8 weeks gestation. Glut 3 (50 to 55-kilodalton protein) immunoreactivity was observed only in the adult inner synaptic layer of the retina. Neither Glut 4 nor Glut 5 was expressed in any occular tissue at any age examined. These results suggest that Glut 1 is the main glucose transporter of the human eye and that it is ontogenically conserved. In contrast, Glut 3 is associated with selective neuronal processes, and its expression is developmentally altered.

Adult↗

PubMed1993

The blood-brain barrier glucose transporter is conserved in preterm and term newborn infants.

Glucose, an essential substrate for brain oxidative metabolism, is transported across the adult blood-brain barrier by Glut 1, a facilitative glucose transporter. Employing postmortem human brain samples and Western blot analysis, we demonstrated the presence of a 47-55 kilodalton Glut 1 protein in preterm and term newborn. The level of Glut 1 in both the preterm (24-33 weeks; n = 12) and term (38-40 weeks; n = 4) neonates was comparable to that of the adult (n = 5). Using paraffin brain sections and immunohistochemical analysis, in the preterm (24-25 weeks) and term (40 weeks) infant, similar to the adult we demonstrated the presence of Glut 1 in microvascular endothelial cells which constitute blood-brain barrier forming cells. The ontogenic conservation of the blood-brain barrier Glut 1 make detecting defective glucose transport across the neonatal blood-brain barrier feasible. Genetic or acquired defects in Glut 1 can impede the transport of glucose across the blood-brain barrier, thereby, resulting in irreversible neurological compromise during infancy. Earlier detection during the neonatal period, and appropriate intervention, may set the stage for altering the outcome of affected infants.

Adolescent↗

PubMed1993

Effect of maternal diabetes on the expression of genes regulating fetal brain glucose uptake.

Diabetes alters adult brain glucose uptake and glucose transporter 1 gene expression. To investigate the effect of diabetes on genes regulating fetal brain glucose uptake, we examined the effect of moderate (blood glucose 10-16.7 mM, normoinsulinemia) and severe (blood glucose > 16.8 mM, hypoinsulinemia) maternal diabetes on the expression of genes regulating fetal brain glucose uptake in the genetically nonobese diabetic mouse. In the moderately diabetic state, a 50% decline in fetal brain GLUT1 mRNA levels was associated with a 20% increase in the corresponding GLUT1 protein levels. Simultaneously, although fetal brain GLUT3 mRNA and protein levels were barely detectable, no change in hexokinase I enzyme mRNA, protein (115,000 and 100,000 M(r)) or activity, was noted. In the severe form of maternal diabetes GLUT1 protein was unchanged, GLUT3 protein levels remained low, and a 2- to 3-fold increase in the lower molecular form of the hexokinase I protein (100,000 M(r)) and enzyme activity occurred. These observations suggest that moderate and severe forms of maternal diabetes do not affect the fetal brain glucose transporter levels to a physiologically significant extent. The severe form of maternal diabetes, however, enhances 1.5- to 3-fold the expression and activity of hexokinase I. This enzyme mediates the rate-limiting step in brain glucose metabolism, namely the intracellular conversion of glucose to glucose-6-phosphate.

Animals↗

PubMed1992

Developmental regulation of insulin in the mammalian central nervous system.

We delineated the ontogeny of rabbit brain insulin concentrations to define the regulatory role of development on this hormone in the central nervous system. Employing a sensitive ELISA, we observed higher concentrations in the late gestation fetal brain (approximately 80-90 ng/g) and early neonatal brain (approximately 195 ng/g) in comparison to the adult (approximately 32 ng/g; P less than 0.01). Further, we characterized this hormone to determine the identity of insulin (or an insulin-like substance) in brain. Employing porcine/bovine or rabbit insulin as standards, we observed that brain insulin mimicked authentic insulin in its migration on SDS-polyacrylamide and native gel electrophoresis, immunogenicity on Western blot analysis, and its elution profile on immunoaffinity column chromatographic, and high performance liquid chromatographic separation. We then examined the developmental effects on circulating and cerebrospinal fluid (CSF) radioimmunoassayable insulin levels. No statistically significant differences (ANOVA) existed through development in either the serum or CSF insulin levels. Employing multiple regression analysis, no correlation was evident between brain and either serum or CSF insulin concentration. A search for insulin mRNA by Northern blot analysis yielded minute amounts of atypical large sized transcripts. We conclude that the insulin peptide in the central nervous system closely resembles (or is identical to) circulating insulin in many properties and that there is a developmental increase in brain insulin concentrations, the maximal peak occuring in the late gestation fetus and early neonate. Insulin concentrations in brain demonstrate no conventional relationship to either the serum or CSF insulin levels, suggesting an additional source of peptide, which contributes beyond that which is available via the circulation. The amounts of insulin present within the central nervous system are minute (difficult to detect) but in the range (10-100 ng) where the hormone can interact with either insulin or insulin-like growth factor I (IGF-I) receptors that are abundantly present on developing brain cells, thereby executing the biological function of the hormone.

Aging↗

PubMed1992

The mammalian glucose transporters.

We have described the properties of glucose transporters expressed in several mammalian tissues and have summarized some of the adaptations that take place involving these molecules in various normal and abnormal states. With the exception of a few cell types, such as adipocytes and skeletal muscle, glucose transport is not a rate-limiting step in cellular glucose metabolism, and other substrates may be equally important for cellular metabolism. Nevertheless, an understanding of the mechanisms behind the regulation of glucose transport in individual tissues may facilitate an understanding of in vivo glucose utilization and clearance processes as they relate to normal and disease states. Although adult studies provide an impetus toward a mechanistic approach in preventing and treating various disease states involving derangements in glucose homeostasis, there remains a need for similar studies in the fetus and newborn. These developmental studies should help unravel the fetal/neonatal responses to normal and abnormal hormonal and substrate milieu.

Animals↗